Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senicapoc in Progressive Fibrotic ILD and IPF
NCT06714123Phase 2Recruiting
- Sponsor
- Vejle Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) comparing Senicapoc with Placebo (2 arms). Primary endpoint: Rate of decline of forced vital capacity (FVC) at 26 weeks. Started Aug 2025; status: recruiting.
02
Drugs
senicapoc
03
Conditions
interstitial lung disease (ILD)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06714123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714123.